Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
World J Gastroenterol ; 22(14): 3735-45, 2016 Apr 14.
Article in English | MEDLINE | ID: mdl-27076758

ABSTRACT

AIM: To investigate the protein expression of phosphatase and tensin homolog (PTEN) in human liver biopsies of patients with alcoholic and non-alcoholic liver disease. METHODS: PTEN protein expression was assessed by immunohistochemistry in formalin-fixed, paraffin-embedded liver sections of patients with non-alcoholic fatty liver disease (NAFLD) (n = 44) or alcoholic liver disease (ALD) (n = 25). Liver resections obtained from 3 healthy subjects candidate for partial liver donation served as controls. Histological evaluations were performed by two experienced pathologists, and diagnoses established based on international criteria. The intensity of the PTEN staining in nuclei was compared between steatotic and non-steatotic areas of each liver fragment analyzed. For each liver specimen, the antibody-stained sections were examined and scored blindly by three independent observers, who were unaware of the patients' clinical history. RESULTS: In healthy individuals, PTEN immunostaining was intense in both the cytoplasm and nuclei of all hepatocytes. However, PTEN was strongly downregulated in both the nucleus and the cytoplasm of hepatocytes from steatotic areas in patients with NAFLD, independently of the disease stage. In contrast, no changes in PTEN protein expression were observed in patients with ALD, regardless of the presence of steatosis or the stage of the disease. The degree of PTEN downregulation in hepatocytes of patients with NAFLD correlated with the percentage of steatosis (r = 0.3061, P = 0.0459) and the BMI (r = 0.4268, P = 0.0043). Hovewer, in patients with ALD, PTEN expression was not correlated with the percentage of steatosis with or without obesity as a confounding factor (P = 0.5574). Finally, PTEN expression level in steatotic areas of ALD patients was significantly different from that seen in steatotic areas of NAFLD patients (P < 0.0001). CONCLUSION: PTEN protein expression is downregulated early in NAFLD, but not in ALD. PTEN immunohistochemical detection could help in the differential diagnosis of NAFLD and ALD.


Subject(s)
Fatty Liver, Alcoholic/diagnosis , Liver/enzymology , Non-alcoholic Fatty Liver Disease/diagnosis , PTEN Phosphohydrolase/blood , Adult , Aged , Aged, 80 and over , Biomarkers/analysis , Biopsy , Case-Control Studies , Diagnosis, Differential , Down-Regulation , Fatty Liver, Alcoholic/enzymology , Female , Humans , Immunohistochemistry , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/enzymology , Observer Variation , Predictive Value of Tests , Reproducibility of Results
2.
Int J Surg Pathol ; 24(4): 366-72, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26842345

ABSTRACT

Denosumab has shown promising results in the management of giant cell tumor of bone, a primary bone tumor with locally aggressive behaviour. We report a case of premature denosumab interruption due to radiological and clinical tumor expansion of a giant cell tumor of the distal ulna. Although denosumab is known to induce tumor regression, with progressive ossification and loss of the characteristic morphology of giant cell tumor of bone, the ulnar tumor specimen showed a moderately to highly cellular proliferation of short spindle-shaped cells, and no osteoclast-like giant cells. There were no abnormal mitotic figures. We considered the surgical specimen as a giant cell tumor of bone with partial regression after prematurely interrupted denosumab treatment. This case illustrates the diagnostic issues of an initially unfavourable evolution raising concern for malignancy, and the difficulties in histological assessment of a partially treated giant cell tumor of bone, that may mimic osteosarcoma.


Subject(s)
Antineoplastic Agents/administration & dosage , Bone Neoplasms/pathology , Denosumab/administration & dosage , Giant Cell Tumor of Bone/pathology , Ulna/drug effects , Adult , Bone Neoplasms/drug therapy , Bone Neoplasms/genetics , Diagnosis, Differential , Giant Cell Tumor of Bone/drug therapy , Giant Cell Tumor of Bone/genetics , Histones/metabolism , Humans , Male , Osteosarcoma/diagnosis , Osteosarcoma/pathology , Polymerase Chain Reaction , Ulna/pathology
3.
Hepatology ; 54(1): 38-49, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21465511

ABSTRACT

UNLABELLED: Hepatitis C virus (HCV) perturbs the host's lipid metabolism and often results in hepatic steatosis. In nonalcoholic fatty liver disease, the intrahepatic down-regulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a critical mechanism leading to steatosis and its progression toward fibrosis and hepatocellular carcinoma. However, whether an HCV infection triggers the formation of large lipid droplets through PTEN-dependent mechanisms is unknown. We assessed PTEN expression in the livers of patients infected with HCV genotype 1 or 3 with or without steatosis. The role of PTEN in the HCV-induced biogenesis of lipid droplets was further investigated in vitro with hepatoma cells transduced with the HCV core protein of genotype 1b or 3a. Our data indicate that PTEN expression was down-regulated at the posttranscriptional level in steatotic patients infected with genotype 3a. Similarly, the in vitro expression of the HCV genotype 3a core protein (but not 1b), typically leading to the appearance of large lipid droplets, down-regulated PTEN expression by a mechanism involving a microRNA-dependent blockade of PTEN messenger RNA translation. PTEN down-regulation promoted in turn a reduction of insulin receptor substrate 1 (IRS1) expression. Interestingly, either PTEN or IRS1 overexpression prevented the development of large lipid droplets, and this indicates that the down-regulation of both PTEN and IRS1 is required to affect the biogenesis of lipid droplets. However, IRS1 knockdown per se did not alter the morphology of lipid droplets, and this suggests that other PTEN-dependent mechanisms are involved in this process. CONCLUSION: The down-regulation of PTEN and IRS1 is a critical event leading to the HCV genotype 3a-induced formation of large lipid droplets in hepatocytes.


Subject(s)
Down-Regulation/physiology , Hepacivirus/physiology , Hepatocytes/metabolism , Hepatocytes/virology , Lipid Metabolism/physiology , PTEN Phosphohydrolase/metabolism , Viral Core Proteins/physiology , Adult , Aged, 80 and over , Biopsy , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Cells, Cultured , Fatty Liver/metabolism , Fatty Liver/pathology , Female , Genotype , Hepacivirus/genetics , Hepatocytes/pathology , Humans , Insulin Receptor Substrate Proteins/metabolism , Liver/metabolism , Liver/pathology , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Male , Middle Aged
4.
Acta biol. colomb ; 14(3): 217-222, dic. 2009.
Article in Spanish | LILACS | ID: lil-634927

ABSTRACT

Se han desarrollado dos métodos para la medición cuantitativa de la actividad proteasa basados en la prueba de la película fotográfica. Una prueba discontinua puede ser implementada mediante la cuantificación de la cantidad de pigmento remanente en la película con cualquier programa de edición de imágenes. La medición continua de la actividad proteasa se puede obtener a través del cambio de absorbancia generado por la liberación de las sales de plata unidas al negativo fotográfico si se cuenta con un espectrofotómetro equipado con una celda con agitación.


Two quantitative protease assays have been developed based on the classic photographic film test. A discontinuous assay can be performed by measuring the amount of pigment remaining in the film with any image editor software. A continuous assay can be implemented by the measuring the release of silver halide salts bonded in the film using a recording spectrophometer equipped with a Peltier Cell.

SELECTION OF CITATIONS
SEARCH DETAIL
...